Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline

Background: A new, effective anti-tuberculosis (TB) regimen containing bedaquiline (BDQ) and pyrifazimine (TBI-166) has been recommended for a phase IIb clinical trial. Preclinical drug–drug interaction (DDI) studies of the combination of BDQ and TBI-166 have been designed to support future clinical...

Full description

Bibliographic Details
Main Authors: Yangming Ding, Haiting Liu, Furun Wang, Lei Fu, Hui Zhu, Shuang Fu, Ning Wang, Xiaomei Zhuang, Yu Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
bedaquiline
drug-drug interaction
N-desmethyl-bedaquiline
pyrifazimine
tuberculosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1154780/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1154780/full

Similar Items